Ocuphire Pharma, Inc. announced that it has entered into common stock purchase agreement with new investor Lincoln Park Capital Fund, LLC, a fund managed by Lincoln Park Capital, LLC to issue common shares for the gross proceeds of $50,000,000 on August 10, 2023. Upon the execution of the Purchase Agreement, the Company issued 246,792 shares of common stock to Lincoln Park and paid Lincoln Park $40,000, which together represents the fee for Lincoln Park?s commitment to purchase shares of the Company?s common stock under the Purchase Agreement. The investor can purchase up to $50,000,000 common shares over a 30-month period at prices per share as computed under the Purchase Agreement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.68 USD | -.--% | -4.55% | -44.19% |
May. 10 | Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 11 | Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.19% | 43.55M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- OCUP Stock
- News Ocuphire Pharma, Inc.
- Ocuphire Pharma, Inc. announced that it expects to receive $50 million in funding from Lincoln Park Capital, LLC